Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Epic Sciences Awarded a Phase II SBIR Contract from NCI/NIH to Develop a Lung Cancer Diagnostic Blood Test

Published: Friday, January 25, 2013
Last Updated: Friday, January 25, 2013
Bookmark and Share
New way to detect cancer based on circulating tumor cells in the blood could improve clinical diagnosis and inform personalized treatments.

Epic Sciences, Inc. announced receipt of a Phase II contract from the Small Business Innovation Research (SBIR) program supported by the National Cancer Institute (NCI) and the National Institutes of Health (NIH). The contract will fund the further development of an assay to identify and characterize circulating tumor cells (CTCs) in lung cancer patients. The results of this contract are expected to provide a basis for the development of new cancer diagnostic products.

“The highly competitive SBIR program funded by federal research dollars is essential for translating innovative technologies into products that can improve the health, well-being and security of the nation,” said David Nelson, Ph.D., president and CEO of Epic Sciences. “Epic will use the SBIR funds to further develop and clinically validate a new diagnostic test to detect and characterize lung cancer using a blood-based test based on our advanced rare-cell detection platform technology. Epic’s technology, as applied both in this contract and with our eight pharmaceutical partners, is well positioned to have a major impact on the way cancer is diagnosed and treated.”

The research grant entitled, “Circulating Tumor Cell Enumeration Product,” builds upon the successful completion of a Phase I grant of the same name, which was previously awarded to Epic. The Phase I and II grants total approximately $1.2 million. In Phase I, Epic developed a clinically useful and commercially relevant method for identifying and enumerating CTCs. In Phase II, Epic will extend this work to finalize the diagnostic test and validate it clinically in patients with suspected lung cancer.

“The lungs are sensitive and difficult tissues to access for biopsies and, as a result, many patients lack adequate biopsy material for diagnostic testing. A blood test for lung cancer could provide a better tolerated, less risky, and more effective strategy for diagnosing lung cancer patients. Beyond finding cancer cells in the blood, the Epic test is also designed to molecularly characterize circulating tumor cells to guide personalize treatment options,” said Dr. Nelson. “Because a blood test can be performed repeatedly, we are also investigating the ability to monitor treatment effectiveness and disease status. Ultimately, we hope that these tests will help to get the right therapy to the right patient at the right time.”

About Circulating Tumor Cells (CTCs)

CTCs are cells that escape from solid tumors, enter the bloodstream where they travel and eventually cause cancer metastasis. Today, solid cancers are first detected by invasive biopsies, which cannot be used repeatedly and may be ineffective in understanding metastatic risk, disease progression, treatment effectiveness and recurrence identification. A blood test that can accurately detect and profile biomarkers on CTCs is easy to conduct frequently and should be able to provide essential, real-time information about disease status to tailor treatments to a patient’s specific cancer and response.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Education and Expense: The Barriers to Mass Spectrometry in Clinical Laboratories?
Here we examine the perceived barriers to mass spec in clinical laboratories and explore the possible drivers behind the recent shift in uptake of the technology in clinical settings.
Adult High Blood Pressure Risk Identifiable in Childhood
Groups of people at risk of having high blood pressure and other related health issues by age 38 can be identified in childhood, new University of Otago research suggests.
Potential New Diagnosis and Therapy for Breast Cancer
Scientists at the University of York, using clinical specimens from charity Breast Cancer Now’s Tissue Bank, have conducted new research into a specific sodium channel that indicates the presence of cancer cells and affects tumour growth rates.
Paving the Way for Diamonds to Trace Early Cancers
Researchers from the University of Sydney reveal how nanoscale 'diamonds' can light up early-stage cancers in MRI scans.
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Horse Illness Shares Signs of Human Disease
Horses with a rare nerve condition have similar signs of disease as people with conditions such as Alzheimer’s, a study has found.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
The Age of Humans Controlling Microbes
Engineered bacteria could soon be used to detect environmental toxins, treat diseases, and sustainably produce chemicals and fuels.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos